Biotech Startups
9,909 companies tagged Biotech, with their investors and founders.
Vera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant. The company was founded by a physician and operates as a clinical-stage biotech with a patient-centered approach to drug development.
3 investors
Vertoro is a bio-based chemicals company that converts woody and agricultural residues into green alternatives to fossil crude oil for use as platform products in materials, chemicals, and fuels. The company operates a scalable production platform validated at Technology Readiness Level 6 and serves industrial customers across oil, shipping, and chemical sectors seeking sustainable substitutes.
3 investors
Vibe Bio funds and supports overlooked drug development programs by combining AI and capital to identify promising treatments and reduce funding gaps. The company serves biotech developers working on life-changing cures that lack traditional funding pathways.
3 investors
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
3 investors
Vilya designs novel macrocycles using AI and computational biology to create medicines that don't exist in nature. The company develops therapeutics for disease by generating entirely new molecules with the targeting precision of antibodies but in pill form.
3 investors
Vir Biotechnology develops treatments for infectious diseases and oncology, leveraging immunology-focused scientific capabilities. The company targets patients with unmet medical needs across these therapeutic areas.
3 investors
Viridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.
3 investors
Virtual Incision develops a miniaturized robotic-assisted surgery (miniRAS) system called MIRA, designed to fit within hospitals' existing infrastructure. The company targets patients, surgeons, and healthcare facilities in the surgical robotics and medical device market.
3 investors
3 investors
Vivodyne is a bio-AI company that develops lab-grown human tissues and robotic systems to generate causal biological data for therapeutic development. The platform produces high-resolution phenomic, transcriptomic, and proteomic data from human tissue models to enable drug discovery and development.
3 investors
Volta develops a hardware and software platform for genomics sample preparation that automates the extraction of biological information. The company serves researchers, laboratories, and healthcare organizations working in genomics, disease control, forensic science, and medicine.
3 investors
Vytala is a foodtech company that develops nutrition solutions to address fat malabsorption and other nutrient deficiencies. The company focuses on clinical nutrition with an emphasis on improving health outcomes through innovative food science.
3 investors
Vytelle offers an integrated technology platform for cattle producers to accelerate genetic progress and enable individual animal management. Its tools support breeding and performance decisions aimed at producing more meat and milk with fewer inputs.
3 investors
WeedOUT develops a biological herbicide using proprietary sterile weed pollen to control resistant weeds in agriculture. The technology prevents viable seed formation in target weed species, addressing herbicide resistance while integrating into existing weed management programs.
3 investors
WuXi AppTec is a global Contract Research, Development and Manufacturing Organization (CRDMO) that provides integrated drug development services spanning chemistry, biology discovery, preclinical testing, and clinical research across Asia, Europe, and North America. The company serves pharmaceutical innovators seeking to accelerate the development and manufacturing of new therapies in a cost-effective manner.
3 investors
Xeltis develops implantable vascular devices that transform into living tissue using Restorex supramolecular polymer technology. The company targets patients requiring hemodialysis vascular access or cardiovascular replacements.
3 investors
3 investors
Yali develops fermentation technology to produce sustainable fats and lipids for alternative dairy products like ice cream, butter, and milk, using fewer inputs than conventional sources.
3 investors
Y-Biologics (μμ΄λ°μ΄μ€λ‘μ§μ€) develops antibody-based drugs using its antibody discovery, fully human antibody library, and antibody engineering technologies, working through its own pipeline and partner collaborations. Its programs include next-generation immuno-oncology therapies such as Multi-AbKine, a multi antibody-cytokine fusion aimed at cancers resistant to existing immunotherapies, along with bispecific antibodies, VHH nanobodies, pH-sensitive antibodies, and ADC antibodies.
3 investors
Yemaachi creates a diverse cancer bio-database to develop oncology drugs effective across diverse patient populations. The company develops precision oncology research, diagnostics, and therapeutics with a focus on inclusion for global communities.
3 investors
Zentraxa precision-engineers bespoke bio-peptides and biomaterials, including adhesives inspired by marine mollusc chemistry that perform in wet, dirty and submerged conditions. Its products serve industries such as advanced wound care, ostomy bag adhesives, optical/transparent adhesives, and personal care ingredients, integrating into existing manufacturing lines.
3 investors
ZylΓΆ Therapeutics develops therapeutic delivery technology, focusing on product development in the biotech and drug-delivery space.
3 investors
Portrai analyzes spatial transcriptomics data together with tissue staining images using AI to generate insights for drug development, supporting drug licensing asset evaluation and drug repurposing. The company applies spatial biology data to innovate the pharmaceutical R&D process.
3 investors
Alpha Fusion is a Japanese biotechnology company developing targeted alpha therapy drugs based on Astatine-211 (211At) to treat cancer with reduced side effects to healthy tissue.
3 investors